TradeOrgs
  • Stocks
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← All stocks

🇮🇳AJANTPHARM

AJANTPHARM

NSE
₹3,326.30
▲ ₹397.10 (+13.6%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 03 Jul 2026
H ₹3,506.90L ₹2,622.20+23.2%
₹3.51K₹3.33K₹3.15K₹2.98K₹2.8K₹2.62K₹3.33K
RSI (14)
Intraday · 15-minSell-15RSI 40SidewaysMACD Bearishfor day-trading context — not advice

Technical signal

Strong buy+60
RSI (14)63
oversold 30overbought 70
Trend
Uptrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
above
vs 50-day
above
vs 200-day
above
Support
₹2,945.00
Resistance
₹3,506.90
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2025-09-29 → 2026-07-03

Strategy return
+22.4%
Buy & hold
+37.2%
Trades
5
Win rate
40%

₹1,00,000.00 invested would be worth ₹1,22,087.71 (+22.1%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Ajanta Pharma Limited· Drug Manufacturers - Specialty & Generic

source: yahoo

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Headquarters
Mumbai, India
www.ajantapharma.com ↗

Fundamentals

source: yahoo
Market cap
₹41.56KCr
P/E
39.4
P/B
9.2
EPS
₹84.49
Div yield
1.7%
Profit margin
19.4%
ROE
25.4%
Debt / Equity
0.06
Beta
0.18
52-week range
₹2,329.90 – ₹3,506.90
52-week low · ₹2,329.9085% of rangehigh · ₹3,506.90

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:— Neutral1↑ · 1↓ · 6–
  • Tennessee deputy spent seized drug money on Apple gear for his family — now he owes $339K in pension clawbacks— Neutral
    Moneywise · 04 Jul 2026
  • Jim Cramer on Cardinal Health: “It’s Been a Real Stalwart, and I Don’t Think It’s Done”— Neutral
    Insider Monkey · 04 Jul 2026
  • Jim Cramer Says He Bets “The Gains in CVS Will Be Long-Lasting”▲ Positive
    Insider Monkey · 04 Jul 2026
  • Jim Cramer Says He Would Avoid Blue Owl and Prefers Blackstone

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

— Neutral
Insider Monkey · 04 Jul 2026
  • Jim Cramer on Palantir: “This Is the Fastest Grower of the Stocks I Follow, and It’s Been Crushed”— Neutral
    Insider Monkey · 04 Jul 2026
  • EPR's CFO Sold Shares at a Premium — Here's the Bet Behind the Stock— Neutral
    Motley Fool · 04 Jul 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.